Scotiabank analyst Greg Harrison lowered the firm’s price target on Travere Therapeutics (TVTX) to $30 from $32 and keeps an Outperform rating on the shares. The company recently presented updated data for its Filspari in IgA nephropathy and focal segmental glomerulosclerosis, reiterating the drug’s “robust clinical profile,” the analyst tells investors. While Vanrafia may out pressure on new patient starts, the firm believes Filspari’s launch should continue upward due to the drug’s differentiated mechanism and broader label.

Stay Ahead of the Market:

Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using  Tipranks' Stock Screener.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on TVTX:

Disclaimer & DisclosureReport an Issue

Travere Therapeutics price target raised to $47 from $45 at Canaccord Travere Therapeutics price target lowered to $27 from $31 at BofA Travere Therapeutics price target raised to $31 from $29 at BofA Promising Outlook for Travere Therapeutics: Buy Rating Affirmed Amid Regulatory and Market Opportunities Buy Rating for Travere Therapeutics Driven by sNDA Submission and Market Potential in FSGS

View Comments